<DOC>
	<DOC>NCT01713361</DOC>
	<brief_summary>The purpose of this study is: - To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of bleeding and VTE, in patients undergoing total knee arthroplasty. - To compare the efficacy and safety profile of ISIS-FXIRx in patients who achieve less than or equal to 0.2 U/mL FXI activity levels to that of enoxaparin.</brief_summary>
	<brief_title>Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>Give written informed consent Females must be nonpregnant and nonlactating, and either surgically sterile or postmenopausal. Males must be surgically sterile, abstinent, or if engaged in sexual relations of childbearing potential, must use contraception Undergoing elective, primary unilateral total knee arthroplasty Body weight &lt;50 kg Patients at increased risk of bleeding. History of intracranial or intraocular bleeding. History of gastrointestinal and/or endoscopically verified ulcer disease within the past year. History of excessive intra or direct post operative bleeding or a traumatic spinal or epidural anesthesia Brain, spinal, or ophthalmologic surgery within the past 3 months History of clinically significant liver disease in the past year Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values aPTT or PT or INR &gt;ULN Factor IX activity &lt;LLN Factor VIII activity, vWF antigen or Ristocetin cofactor activity &lt;0.5 U/mL FXI activity &lt;0.3 U/mL Urine protein or blood persistently positive by dipstick. In the event of positive test results, eligibility may be confirmed with urine microscopy or 24 hour urine protein measurement as applicable ALT or AST &gt;1.5 x ULN Total bilirubin &gt;ULN Platelet count &lt;150,000 (or history of thrombocytopenia) Hypersensitivity to enoxaparin Anticipated concomitant use of anticoagulants/antiplatelet agents or the NSAID nimesulide that may affect study outcome or any other drug influencing coagulation (except low dose aspirin and short acting NSAIDs with a halflife &lt;20 hours) at least 7 days before surgery or during treatment with ISIS Rx. Anticipated use of indwelling intrathecal or epidural catheters Anemia at Screening Have any other conditions which could interfere with the patient participating in or completing the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>total knee arthroplasty</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>